The Gastrointestinal Cancer Channel is supported with funding from Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESSO 45 | Total neoadjuvant therapy reduces toxicity in locally advanced rectal cancer
Sara Lonardi, MD, Veneto Institute of Oncology, Padua, Italy, discusses multimodal treatment approaches for locally advanced rectal cancer, which typically involves chemotherapy, radiation, and surgery to address tumors with high or medium-high risk factors. Total neoadjuvant therapy, delivered before surgery, enables comprehensive chemotherapy and radiation with more acceptable toxicity profiles compared to adjuvant treatment. This preoperative approach demonstrates promising data regarding disease-free survival and overall survival outcomes. This interview took place at the 2026 European Society of Surgical Oncology (ESSO) Annual Meeting in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
You know, in medical oncology it’s not easy to say that one thing is fitting all the patients, but when we are facing a locally advanced rectal cancer, we know that we have to treat probably with a multi-modal treatment, including chemotherapy, radiation, and surgery. The majority of these tumors have high or medium-high risk factors. Total neoadjuvant therapy is… is able to give the wider amount of chemotherapy and radiation before surgery with a toxicity that is more acceptable compared to after surgery and with the data on the FS and overall survival that are promising in terms of advantage in delivering all the treatment before surgery...
You know, in medical oncology it’s not easy to say that one thing is fitting all the patients, but when we are facing a locally advanced rectal cancer, we know that we have to treat probably with a multi-modal treatment, including chemotherapy, radiation, and surgery. The majority of these tumors have high or medium-high risk factors. Total neoadjuvant therapy is… is able to give the wider amount of chemotherapy and radiation before surgery with a toxicity that is more acceptable compared to after surgery and with the data on the FS and overall survival that are promising in terms of advantage in delivering all the treatment before surgery.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
